MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

Search

Artivion Inc

Slēgts

SektorsVeselības aprūpe

37.56 2.93

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

36.82

Max

37.83

Galvenie mērījumi

By Trading Economics

Ienākumi

-4.1M

2.4M

Pārdošana

2.6M

116M

P/E

Sektora vidējais

159.286

66.418

Peļņas marža

2.092

Darbinieki

1,800

EBITDA

-6M

13M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+36.41% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 4. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-275M

1.6B

Iepriekšējā atvēršanas cena

34.63

Iepriekšējā slēgšanas cena

37.56

Ziņu noskaņojums

By Acuity

50%

50%

185 / 348 Rangs Healthcare

Artivion Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 10. apr. 17:04 UTC

Galvenie tirgus virzītāji

FDA Rejects Replimune's Melanoma Drug for a Second Time

2026. g. 11. apr. 00:00 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Big Yachts, Big Bucks -- Barrons.com

2026. g. 10. apr. 21:55 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Warrants Are an Underappreciated Aspect of Warner Bros. Deal -- Barrons.com

2026. g. 10. apr. 21:01 UTC

Peļņas

Cango Inc.: Files Annual Report on Form 20-F With SEC

2026. g. 10. apr. 20:50 UTC

Tirgus saruna

Energy & Utilities Roundup: Market Talk

2026. g. 10. apr. 20:50 UTC

Tirgus saruna
Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

2026. g. 10. apr. 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 10. apr. 20:31 UTC

Tirgus saruna

Convenience Store Traffic Slows as Gas Prices Rise -- Market Talk

2026. g. 10. apr. 20:10 UTC

Iegādes, apvienošanās, pārņemšana

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

2026. g. 10. apr. 19:15 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2026. g. 10. apr. 19:15 UTC

Tirgus saruna

Oil Futures Settle Lower With Focus on U.S.-Iran Talks -- Market Talk

2026. g. 10. apr. 19:08 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 10. apr. 19:08 UTC

Tirgus saruna

U.S. Natural Gas Futures End Week Lower -- Market Talk

2026. g. 10. apr. 18:38 UTC

Tirgus saruna

Canada's Job Market Showing Soft Demand, Structural Decline in Supply -- Market Talk

2026. g. 10. apr. 18:25 UTC

Tirgus saruna
Galvenie ziņu notikumi

Precious Metals Finish With Weekly Gains -- Market Talk

2026. g. 10. apr. 18:05 UTC

Tirgus saruna

Rising Commodity Prices Seen Carrying More Weight Than Jobs Data for Bank of Canada Watchers -- Market Talk

2026. g. 10. apr. 17:31 UTC

Tirgus saruna
Galvenie ziņu notikumi

U.S. Oil Rig Count Unchanged This Week At 411 -- Market Talk

2026. g. 10. apr. 17:26 UTC

Peļņas

Big Banks' Profits Set to Rise Even as 'Wall of Worry' Looms -- Barrons.com

2026. g. 10. apr. 17:10 UTC

Tirgus saruna

White House Defense of Stablecoin Yields Is Welcome Move, Grayscale Says -- Market Talk

2026. g. 10. apr. 17:00 UTC

Galvenie ziņu notikumi

Construction Business Taking a Hit From Iran Conflict -- WSJ

2026. g. 10. apr. 16:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 10. apr. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 10. apr. 16:12 UTC

Peļņas

Partners Group CEO: Group Well Positioned to Navigate Current Complex Environment

2026. g. 10. apr. 16:11 UTC

Peļņas

Partners Group: Traditional Programs Contributed $3.3B

2026. g. 10. apr. 16:10 UTC

Peļņas

Partners Group: $5B of New Commitments Came From Bespoke Solutions

2026. g. 10. apr. 16:10 UTC

Peļņas

Partners Group: That Is Across All Private Markets Asset Classes and Client Strategies

2026. g. 10. apr. 16:10 UTC

Peļņas

Partners Group 1Q New Client Demand $8.3B

2026. g. 10. apr. 16:09 UTC

Peļņas

Partners Group Continued to See Positive Fundraising Momentum in 1Q

2026. g. 10. apr. 15:54 UTC

Iegādes, apvienošanās, pārņemšana

Plenitude Completes Acquisition of Acea Energia

2026. g. 10. apr. 15:38 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Artivion Inc Prognoze

Cenas mērķis

By TipRanks

36.41% augšup

Prognoze 12 mēnešiem

Vidējais 51.33 USD  36.41%

Augstākais 58 USD

Zemākais 42 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Artivion Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

6 ratings

6

Pirkt

0

Turēt

0

Pārdot

Noskaņojums

By Acuity

185 / 348 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Artivion Inc

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
help-icon Live chat